BACKGROUND: Statin dose guidelines for patients with peripheral artery disease (PAD) are largely based on coronary artery disease and stroke data. The aim of this study is to determine the effect of statin intensity on PAD outcomes of amputation and mortality.
P
eripheral artery disease (PAD) is a highly prevalent atherosclerotic syndrome affecting 8 to 12 million individuals in the United States and is associated with significant disability, morbidity, and mortality. 1, 2 The prevalence is 15% to 20% in individuals >65 years. 3 There are 148 000 major amputations done annually in the United States because of PAD. 4 Annual mortality (8.2%) is higher among patients with PAD than after a myocardial infarction (6.3%). 5 Despite the significant limb and cardiovascular outcomes in PAD, there is poor risk factor modification relative to other atherosclerotic diseases like coronary artery disease (CAD) or stroke. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In 2013, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults recommended that all patients with clinically apparent atherosclerotic cardiovascular disease should be initiated on high-intensity statins (3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors). 16 The guidelines cited that the level of evidence for PAD was low. The Heart Protection Study is the only randomized clinical trial to include a large number of patients with PAD and showed a reduction in the rate of first major vascular and peripheral vascular events in a subcohort of simvastatin-treated patients with PAD. 17, 18 PAD remains an understudied disease population, 19 and most data or risk estimates are obtained from subcohorts of patients with CAD or isolated from population group estimates. 5, 20, 21 Given the lack of evidence supporting the use of high-intensity statins in patients with PAD, the objective of our study was to determine the effect of statin intensity (based on 2013 ACC/AHA guidelines) on the PAD outcomes of amputation and mortality. We also sought to evaluate the variation in prescription of statin intensity over time and by the presence of comorbid atherosclerotic disease conditions in a large PAD cohort.
METHODS
This study was approved by the Emory University institutional review board and Atlanta VAMC Research and Development Committee. Informed consent was waived for a retrospective cohort study design with no human subject contact and minimal privacy risks. The data and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because they contain subject identifiers. However, the analytic approach is described in sufficient detail in the article to allow researchers with VA data access to reproduce and replicate results.
Sample and Database
Patients with incident PAD were identified from the national Veterans Health Administration data using a validated algorithm 22 
Study Exposure and Outcome
The exposure was defined as the highest statin dose used/ prescribed to a veteran around their PAD diagnosis date (6 months before and after). The statin dose/intensity was defined by the 2013 ACC/AHA guidelines (Table I in the online-only Data Supplement). Low-and moderate-intensity statins were combined into 1 category because <4% subjects were on low-intensity statins. Because the simvastatin 80-mg dose is not part of the 2013 ACC/AHA guidelines and is no longer prescribed in the Veterans Health Administration pharmacy because of concerns of myotoxicity, 24 we excluded it from the main Cox models and propensity-matched analyses, but included it in a sensitivity analysis.
The outcomes of interest were (1) incident amputation (mid/hind foot, below-and above-knee amputations) and (2) death after PAD diagnosis during follow-up (International Classification of Diseases, Ninth Revision diagnosis codes and procedure codes in Table II in the online-only Data Supplement). The follow-up continued through outcome occurrence or December 31, 2015 (whereupon the subject was censored). Patients with prior amputations were included in the analysis, but incident amputation was defined as the first amputation after PAD diagnosis. Long-term survival of
Clinical Perspective
What Is New?
• Our study shows that use of high-intensity statins early in peripheral artery disease (PAD) diagnosis is better in terms of decreasing the risk of amputation and death in patients with PAD.
• Use of low-and moderate-intensity statins also has beneficial effects for limb loss and mortality in comparison with no use of statins.
• There is still considerable underuse and recognition of the role of secondary prevention using statins in patients with PAD, especially in those without coronary disease.
What Are the Clinical Implications?
• On diagnosis of PAD, a patient should be started on the highest intensity of statin that can be tolerated, much like coronary artery disease, to reduce their lifetime risk of amputation and death.
• Emphasis needs to be laid on early diagnosis and treatment of PAD, especially in the absence of coronary artery disease, by all providers, including primary care physicians, cardiologists, and vascular specialists.
Circulation. 
Covariates
A comprehensive list of patient covariates was abstracted from the database; all variables were measured as close as possible to the PAD diagnosis date with a 6-month limit on either side. Covariates included demographics (age at PAD diagnosis, sex, race), socioeconomic status as defined by median household income of the patient's most recent residential zip code tabulation area, body mass index, smoking (current versus former versus never smoker, classified using a validated method for text-based health factors 25 ), antiplatelet drug use (aspirin, clopidogrel, other), cilostazol use, patient comorbidities (diabetes mellitus [DM] , hypertension, CAD, chronic obstructive pulmonary disease, congestive heart failure, atrial fibrillation, carotid artery stenosis, chronic kidney disease or end-stage renal disease, and depression) ( Table II in the online-only Data Supplement), laboratory values (total cholesterol, high-density lipoprotein, low-density lipoprotein, hemoglobin A1c, and serum creatinine), PAD severity (claudication versus rest pain versus ulceration/gangrene versus not specified), and diagnosis year. All variables were abstracted from the national VA Corporate Data Warehouse and VA Medical SAS administrative databases.
Statistical Analysis
Demographic and clinical variables were assessed for the entire cohort and stratified by statin use (none versus low-tomoderate intensity versus high intensity). Continuous variables were expressed as means (±SDs) or as medians (±interquartile ranges) if they were not normally distributed. These were compared by using the Kruskal-Wallis test. Discrete variables were compared using χ 2 tests for proportions. Proportions of missing data were also calculated and compared in the cohort to determine whether data were missing at random (Table III in the online-only Data Supplement). We explored the distribution of statin use over time by 3-year periods and among patients with other atherosclerotic diseases for the full cohort (N=155 647).
For the main analysis comparing statin intensity with outcomes of amputation and mortality, we did a 3-level comparison: high-dose statin users (N=19 301), low-to-moderate dose (N=60 338) statin users, and those not taking statins but following another guideline-directed therapy (antiplatelet drugs including aspirin and clopidogrel, as the active comparator group) (N=28 351) to reduce healthy user bias (patients who initiate a medication [ie, statin in our study] may do better than those who do not because of their healthy behavior rather than the effect of the medication). Unadjusted associations for statin intensity and risk of death and amputation were obtained by using Kaplan-Meier curves over the entire study period accounting for censoring. Subjects were censored on December 31, 2015 in the mortality curves and on death or December 31, 2015 in the amputation curves. Cox proportional hazards regression models were then constructed to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for amputation and death by statin intensity categories with the referent as the active comparator group on antiplatelet medications but no statins (AP only). The Cox proportional hazards models for amputations were cause specific to account for competing risk of death in follow-up. The models adjusted for the listed covariates in Table 1 , with the exception of cholesterol levels, because statin use would impact these measurements and therefore they function as mediating variables.
We then performed propensity score (PS)-matched analysis to further control for possible confounding in 2 subanalyses.
(1) We calculated 3-level PS comparing low-to-moderate-and high-intensity statin users with the active comparator group (AP only) to address confounding by indication. Propensity scores were calculated with logistic regression using all covariates listed in Table 1 , with the exception of cholesterol (impacted by statin use) and hemoglobin A1c (large proportion missing data) and excluding antiplatelet use as a predictor. For this we used a validated SAS macro to execute a 1:1:1 match using a caliper of 0.6 times the SD of the logit of the PS, generating AP-only, low-to-moderate-intensity statin, and high statin intensity trios matched on PS. 26 Prematch histograms of scores were compared to ensure sufficient overlap for matching, and postmatch balance was assessed using pairwise standardized differences in Table IV in the online-only Data Supplement. Cox models stratified on matched trio and adjusting for all PS covariates were run to calculate HRs for low-to-moderateintensity statin versus AP-only group and high-intensity statin versus AP-only group. Tests for trend from AP-only to low-tomoderate to high-intensity statin were also performed. Despite strong observed postmatch balance, we additionally adjusted for all PS covariates to guard against a misspecified score. 27 (2) We made low-to-moderate-intensity statin users as the active comparator to further control for a healthy user bias and provide more closely matched controls. Propensity scores were calculated to match high-intensity statin subjects to those taking low-to-moderate-intensity statins in a 2-level analysis. 27 A validated SAS macro was used to execute a 1:1 nearest-neighbor matching algorithm with a caliper of 0.2 times the SD of the logit of the PS. Prematch histograms of scores were compared to ensure sufficient overlap for matching, and postmatch covariate balance was assessed in Table V in the online-only Data Supplement using standardized differences. Cox models stratified by matched set were then constructed to calculate adjusted HRs among these matched pairs.
The effects of excluding simvastatin 80 mg were evaluated in a sensitivity analysis. Subgroup analysis was done for age, sex, diabetes status, CAD status, and race. All variables were found to meet the proportional hazards assumption via loglog survival curves for amputation and mortality. Wald confidence limits were constructed for all HRs, and an additional test for trend was run to compare the low-to-moderate and high-statin groups.
The statistical analysis was done using SAS version 9.4 (SAS Institute). Two-sided P values of <0.05 were considered statistically significant.
RESULTS

Statin Use in Veterans With PAD
Our cohort consisted of 155 647 veterans with incident clinical PAD with a median follow-up of 5.9 years. The 
Unadjusted Associations of Statin Intensity With Amputation and Mortality
There were 10 824 amputations and 63 287 deaths identified during follow-up. The median time to outcome was 0.98 years for amputation and 3.6 years for mortality. Figure 2 provides the Kaplan-Meier analysis demonstrating any statin medication use (high-intensity and low-to-moderate-intensity statins, as well) at the time of PAD diagnosis having better overall survival and amputation-free survival than the active comparator (AP-only) group, while accounting for censoring over time 
Adjusted Associations of Statin Intensity With Amputation and Mortality
To better delineate the effect of statin intensity on mortality and amputation risk in PAD, we adjusted for a host of confounders. We determined age, the presence of CAD, and year of diagnosis of PAD to be the most important confounders that may affect the use of statin, and the outcomes of interest, as well. We adjusted for these 3 variables using Cox proportional hazards modeling ( Table 2 , adjusted model 2 and Table VI in the online-only Data Supplement), we further adjusted model 1 for additional confounders like race, sex, socioeconomic status, body mass index, serum creatinine, comorbidities (DM, hypertension, congestive heart failure, chronic obstructive pulmonary disease, atrial fibrillation, carotid artery stenosis, depression, and chronic kidney disease or end-stage renal disease), antiplatelet medications, cilostazol, and PAD severity. The hazard of death was 17% lower for low-to-moderate statins (HR, 0.83; 95% CI, 0.81-0.86) and 26% lower for high-intensity statins (HR, 0.74; 95% CI, 0.70-0.77), in comparison with the AP-only active comparator group. The risk of amputation was similarly lower: 19% (HR, 0.81; 95% CI, 0.75-0.86) for low-tomoderate-intensity statin users and 33% (HR, 0.67; 95% CI, 0.61-0.74) lower for high-intensity statin users versus the AP-only group. The HRs for those on highintensity statins were also statistically significantly lower than those on low-to-moderate-intensity statins for both death and amputation, demonstrating a protective doseresponse relationship (test for trend P<0.001).
Propensity Score-Matched Analyses
We found similar results in a PS-matched analysis whether performing a 3-level or a 2-level matched analysis (Table 3, Tables IV and V in 
Sensitivity Analyses
The a priori hypothesis and methodology for our analysis sought to compare outcomes patients with PAD who were using statins classified by intensity in the 2013 ACC/AHA lipid guidelines. However, 21% of the PAD cohort was on simvastatin 80 mg, mostly in the earlier years of the cohort. Therefore, we also ran Cox models as a sensitivity analysis to test whether inclusion of simvastatin 80 mg changed the effect of the statin intensity association with death and amputations. The use of simvastatin 80 mg had a similar risk-lowering effect on death and amputations overall for the PAD cohort as with any statin therapy in comparison with the AP-only group, whereas the association of high-intensity and low-to-moderate-intensity statins remained significant with similar effect sizes as the main model in terms of lower amputation and mortality risk (Table VII in the online-only Data Supplement). P value for high versus low-to-moderate statin use is <0.001 in unadjusted, adjusted model 1, and fully adjusted model 2. PAD indicates peripheral artery disease.
*Model excludes subjects taking simvastatin 80 because that is not part of American College of Cardiology/American Heart Association 2013 lipid guidelines. †Model 1 adjusted for age at cohort entry, PAD diagnosis year, and coronary artery disease. ‡Model 2 adjusted for age at cohort entry, PAD diagnosis year, race, sex, socioeconomic status, body mass index, comorbidities (diabetes mellitus, hypertension, congestive heart failure, chronic obstructive pulmonary disease, atrial fibrillation, carotid disease, depression, chronic kidney disease, and end-stage renal disease), antiplatelet medications, cilostazol, PAD severity (not specified vs claudication vs rest pain vs ulceration/gangrene), and serum creatinine.
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Subgroup Analysis
The 2013 ACC/AHA lipid guidelines are mostly applicable to patients ≤75 years in age, and there is less evidence for statin use in PAD for older patients, blacks, women, and patients with DM. Furthermore, CAD was a main indication for patients already on statins at the time of PAD diagnosis. Therefore, we performed subgroup analysis to explore the association of statin intensity and amputations and mortality in the cohort stratified by age, sex, diabetes status, comorbid CAD (at PAD diagnosis), and race ( Figure 3 ). Individuals on low-to-moderate-intensity and high-intensity statins had similar reduction in amputation and mortality risk regardless of their age categorization. Patients >75 years of age had comparable risk reduction in mortality (HR, 0.5) versus those ≤75 years (HR, 0.73) when using high-intensity statins versus being on antiplatelet medications only but no statins. In terms of limb loss, patients >75 years had a much lower risk of amputation (HR, 0.61) than those ≤75 years (HR, 0.70) when taking high-intensity statins versus only antiplatelet medication and no statin. The number of female patients with PAD (n=1799) was small in the Cox model, thus leading to wide confidence intervals in our estimates. Women still had a significant reduction in mortality while on highintensity statins (HR, 0.72; 95% CI, 0.53-0.98), but the association of statin use with amputation risk was not significant with point estimate >1 (HR, 1.09). Patients with DM and those without DM both showed significant risk reduction with statin use in a dose-response fashion similar to the entire cohort, although the effect of high-intensity statins on mortality and amputation was magnified among patients without DM (mortality HR 
DISCUSSION
Our study is the largest and first of its kind to examine the effect of statin use and intensity on mortality and amputation risk in a large cohort of patients with PAD. We confirmed low prescription of statins for patients with PAD in comparison with those with other wellknown atherosclerotic disease processes such as CAD or carotid disease. We found an inverse dose-response relationship of statin intensity on death and amputation risk with patients on high-intensity statins. Our adjusted analyses showed almost 30% reduction in risk of death and 30% to 40% reduction in risk of major amputation in high-intensity statin users in comparison with those not on statins but on another guideline-directed therapy, ie, antiplatelet medications. Low-to-moderate-intensity statins also had a favorable association with reduced limb loss and mortality, but not to the same degree as high-intensity statins. These findings were robust to adjustment for potential confounding by indication and possible healthy user bias in propensity-matched, sensitivity, and subgroup analyses using active comparator groups. The association of high-intensity statins with risk reduction of cardiovascular end points in the coronary [28] [29] [30] [31] and carotid beds 32, 33 is well known. However, there are no randomized clinical trials or observational studies in PAD to compare high-versus low-to-moderate-intensity statins for PAD outcomes. The HPS study (Heart Protection Study) is the only randomized clinical trial that in- cluded a large subcohort of patients with PAD (n=6748 with PAD, of 20 536) conducted in the United Kingdom. They had a larger proportion of women (26%) and a lower prevalence of smokers (21%), patients with DM (23%) and hypertension (43%) than in our cohort. The study showed simvastatin 40 mg had a 17% reduced incidence of cardiovascular death, 25% reduction in myocardial infarction, coronary revascularization, and stroke, and a 16% reduction in peripheral vascular events (noncoronary revascularization, aneurysm repairs, major am- Stratified Cox proportional hazards models for effect of statin intensity on mortality and amputations in patients with PAD stratified by age, sex, diabetes status, CAD status, and race. Referent group is "None": active comparator group on antiplatelet medications but no statins. HR for high-intensity statin shown as black triangles and low-to-moderate-intensity statins shown as gray squares. CAD indicates coronary artery disease; DM, diabetes mellitus; HR, hazard ratio; and PAD, peripheral artery disease.
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putations, or PAD deaths). 18 In our sensitivity analysis, we found that patients on simvastatin 80 mg did have 16% lower all-cause mortality and 22% lower risk of amputation than those only on antiplatelet medication and no statin, whereas patients on high-intensity statins had larger reductions in amputation (32%) and mortality (26%) risk in comparison with simvastatin 80 mg, and the estimates from the HPS study, as well. Observational studies have shown that the use of any statins in patients with PAD is associated with lower mortality and cardiovascular events. 34, 35 A particularly important, but often understudied outcome in patients with PAD is limbrelated outcomes. Observational studies have shown statin use to be associated with increased walking performance in claudicants, 36, 37 reduced risk of amputation or revascularization, 18, 38 and improved patency of lower extremity vein bypass grafts. 39, 40 Our study confirms the association of statin use with decreased amputation rates, and further highlights the incremental benefit of using high-intensity statins rather than low-to-moderate-intensity statins in eligible patients to improve limb salvage. Postulated mechanisms of this overall benefit of statins include lipid lowering, and the pleiotropic effects of statins, as well, on atherosclerotic plaque. 18, 34, 41 Clinical studies on femoral plaque characteristics have reported high-dose statins to predominantly improve plaque composition or cause plaque regression, leading to a more stable phenotype in PAD. 42, 43 Recent studies have shown that patients with PAD are less likely to receive medical management including statin therapy, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] antiplatelet therapy, 6, 8, [10] [11] [12] [13] 15 glycemic control, 9, 11, 15 hypertension control, [8] [9] [10] [11] [12] 15 and exercise 6 than patients with CAD. The reasons cited include lack of awareness of PAD by providers 6, 7, 9, 11, 12, 15 and patients, 14, 44 lesser perceived risk in PAD, 6, 9, 11, 14, 15 differences in subspecialists managing PAD, 6,14 practice setting (university versus private), 8 racial disparity, 8 lack of regulatory mandates/performance measures, 9, 10, 13, 15 advanced disease at diagnosis, 11 and lack of insurance coverage of PAD rehabilitation.
14 Our findings show the lack of appropriate statin use in a PAD cohort; more than a quarter of the patients did not take statin therapy throughout the study interval. Furthermore, a large percentage of patients with PAD were on low-to-moderate-intensity statins instead of high-intensity statins as recommended.
The ACC/AHA lipid guidelines were published in 2013, and we examined the temporal trends in statin intensity. We found that the percentage of patients not on statins persisted in the 25% to 30% range throughout the study interval 2003 to 2014. An encouraging trend toward greater use of high-intensity statins, 4% in 2003 to 2005 up to 28% in 2012 to 2014 was observed. The undertreatment of PAD is further magnified when comorbidities that require high-intensity statins are considered. In patients with concurrent diagnosis of PAD with either CAD or carotid stenosis, the use of statins in general and high-intensity statins was much higher in our cohort, whereas in patients with only PAD as their sole atherosclerotic disease process, ≈42% were not on any statin medication and only 5.8% were on high-intensity statins. Treatment with ≥2 preventative therapies (including aspirin, statin, and hypertensive control) is associated with a 65% reduced risk of all-cause mortality in individuals with PAD who do not have previously established cardiovascular disease. 12 This further amplifies the need for education and dissemination of the latest evidence and guidelines among primary care/specialist providers caring for PAD, and the development of performance measures to promote use of high-intensity statins in PAD, as well.
Patients on high-intensity statins maybe be inherently different than those not on any statins based on indication for medication use, patient compliance, or adherence to treatment. Therefore, we tested our hypothesis in multiple ways. We first compared statin users with antiplatelet users but not on statins as healthy users (active comparators). Furthermore, we confirmed the association of reduced limb loss and death with high-intensity statin use in a propensity-matched analysis where we alternated the comparison groups between high-intensity versus low-to-moderate-intensity versus AP-only groups, and limiting the analysis to only high-versus low-to-moderate-intensity statin groups, as well, to provide a highly matched control group. In addition, we did sensitivity analysis where addition of the simvastatin 80 mg cohort did not alter the effect sizes or direction of risk for amputations and mortality with statin intensity. The findings also remained significant in their graded (high versus low-to-moderate versus AP-only) association of PAD outcomes with statin intensity in each subgroup analysis for age, race, and the presence of comorbid DM and CAD accounting for differences in indications of statin use. The consistent finding of reduced PAD adverse events with the use of high-intensity statins in our study should prompt further investigation into mechanisms, further observational studies, clinical trials, and consensus guidelines for medical management of PAD.
Our study has several limitations. We only assessed the prevalent statin use within the first year of diagnosis of PAD. Patients could have been started later on appropriate statin therapy. However, our study could be interpreted as indicating that timely initiation of statin or being on a statin already at the time of PAD diagnosis is associated with substantial reduction in death and amputations. We could not separate the statin initiators from the users given the high occurrence of comorbid CAD or other atherosclerotic disease processes that would need statin therapy. However, we did find in our subgroup analysis that non-CAD patients had a similar risk reduction on amputation and death sug-gesting that possible statin initiation for non-CAD patients has similar effects. This is an observational study using administrative data, the data sources are from clinical care records, and the analysis may be susceptible to residual confounding. We have made a significant effort to account for accurate PAD diagnosis, and to perform a comprehensive Cox model. In addition, careful handling of missing data and performance of sensitivity and PS-matched analyses were done to minimize and investigate the possibility of bias. The adherence and patient compliance with prescribed statin dose was not measured in the study; hence, we did not do a time-varying covariate analysis. This should be investigated further in future studies. We conjecture that patient compliance may show more benefit with adherence to high-intensity statin use. Our study is based on Veterans Health Administration data, and it is overwhelmingly made up of male patients with a high prevalence of smoking. Results may differ in a non-VA population.
In conclusion, our study shows an associated benefit between patients on high-intensity statins before or early on diagnosis of PAD to have a lower lifetime risk of death and amputations. Low-to-moderate-intensity statins also reduce the risk of limb loss and mortality in comparison with patients on antiplatelet medications but no statin therapy and may have an important role in patients intolerant of high-intensity statins. Further work is needed to quantify the risk-benefit with patient medication adherence, the effect of statin intensity on disease severity of PAD, and the implementation of strategies to increase statin use in patients PAD, as well.
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